亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台,协助业界发掘知识产权贸易商机,并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权,或是制造商需要购买技术以提高操作效能,又或是知识产权配套服务供应商,你将会从本网站发掘到有用的知识产权贸易资讯。

High-throughput Fluorescent Screening Assay for Inhibitors of Gram-Negative Iron Transport

详细技术说明
Researchers at Kansas State University have developed a patent pending novel fluorescence spectroscopic high-throughput screening assay to help companies and academic researchers identify new antibiotics to use against Gram-negative bacteria. This assay finds molecules that block bacterial iron transport and inhibits the Gram-negative bacteria from being able to utilize iron uptake in the host, person or animal, making them ill.Gram-negative bacteria, of certain types, are becoming resistant to antibiotic drugs. This is a great concern because as available antibiotics are no longer effective against the Gram-negative bacteria, treatment options become limited or nonexistent. Without treatment, there is a threat of increased illnesses and even deaths. The National Institute for Health and the U.S. Public Health Service have focused part of their antibiotic research on these gram-negative resistant bacteria, specifically on the CRE/ESKAPE* pathogens.*CRE – Carbapenem-resistant Enterobacteriaceae; ESKAPE – Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa and EnterobacterDevelopment Status:The current development of this assay has demonstrated efficacy with Escherichia coli (E. coli) pathogens but could be easily adapted to test additional Gram-negative bacterial pathogens. The method could also be adapted to search for iron uptake processes other than those specific to E. coli; this assay can be conceptually applied to CRE/ESKAPE pathogens. Ongoing research is likely to yield data on other pathogenic bacteria in the near future.Advantages:Small amount of cells needed; day-to-day reproducibility of test resultsTesting method is readily adaptable to different pathogensHigh-throughput capability of the testPotential reduction in illness and death with production of new non-resistant antibioticsApplications:Identification of new pharmaceutical candidates for humans or animalsPatent StatusPCT application filed in July 2016.Kansas State University Research Foundation seeks to have discussions with companies that are interested in licensing and/or research collaborations.Interested parties should contact:Kansas State University Institute for Commercialization (KSU-IC)2005 Research Park Circle Manhattan, KS 66502Tel: 785-532-3900 Fax: 785-532-3909E-Mail: ic@k-state.edu
*Abstract
None
国家/地区
美国

欲了解更多信息,请点击 这里
移动设备